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Abstract: 
Aims/Hypothesis: Better understanding of type 2 diabetes and its prevention is a pressing need. Changes 
in human plasma N-glycome are associated with many diseases and represent promising diagnostic and 
prognostic biomarkers. Variations in glucose metabolism directly affect glycosylation through the 
hexosamine pathway, but studies of plasma glycome in type 2 diabetes are scarce. 
Methods: Using chromatographic approach, we analysed N-linked glycans from plasma proteins in two 
populations comprising individuals with registered hyperglycaemia during critical illness (increased risk 
for development of type 2 diabetes) and subjects who stayed normoglycaemic during the same condition 
-  AcuteInflammation (59 cases vs. 49 controls) and AcuteInflammation Replication (52 cases vs. 14 
controls) populations. Additionally, N-glycome was also studied in subjects from FinRisk (37 incident cases 
of type 2 diabetes collected at baseline vs 37 controls), ORCADES (94 subjects with HbA1c > 6.5 % vs 658 
controls) and SABRE cohort studies (307 subjects with HbA1c > 6.5 % vs 307 controls). 
Results: Individuals with increased risk for diabetes type 2 development (AcuteInflammation and 
AcuteInflammation Replication populations), incident cases of type 2 diabetes collected at baseline 
(FinRisk population) and subjects with elevated HbA1c (ORCADES and SABRE populations) all presented 
increased branching, galactosylation and sialylation of plasma protein N-glycans and these changes were 
of similar magnitude. 
Conclusions/Interpretation: Increased complexity of plasma N-glycan structures is associated with higher 
risk of developing type 2 diabetes and poorer regulation of blood glucose levels. Although further research 
is needed, this finding could offer a potential new approach for improvement in prevention of diabetes 
and its complications.  
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BMI-Body Mass Index; CI - confidence interval; UDP - uridine diphosphate; GlcNAc - N-acetylglucosamine; 
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Introduction 
Type 2 diabetes represents one of the major public health challenges globally, having a constantly 
growing prevalence with the global projection of 7.3 % for the year 2025 (1) . Thus, the worldwide agreed 
target is to halt the rise in diabetes cases.  
Intensive research in the past decades resulted in the introduction of new oral and parenteral 
medications that may improve the management of the disease, but early identification of affected 
patients and prompt initiation of the adequate treatment are equally important for reducing long term 
complications, morbidity and mortality. Recognising individuals with increased risk of type 2 diabetes 
development is nowadays of even higher importance, since many potential interventions are available 
which can postpone and maybe even prevent the disease onset.  
It has been recently shown that subjects without a history of diabetes, who developed 
hyperglycaemia (plasma glucose > 7.7 mmol/L) during critical illness are at significantly increased risk of 
developing type 2 diabetes (2; 3). The relative risk (RR) of type 2 diabetes development during five years 
after the acute illness was 5.6 (95% confidence interval (CI) 3.1 to 10.2). The phenomenon probably arises 
from the fact that people who develop hyperglycaemia in critical illness already have a latent disorder in 
glycaemic control. This disorder cannot be detected with the usual screening tests, but manifests in the 
circumstances of severe acute illness due to inflammatory and stress mediators. Individuals without this 
latent disorder manage to overcome hyperglycaemic effects of stress, and inflammation and remain 
normoglycaemic.  After the acute illness subsides, individuals who presented with hyperglycaemia 
become normoglycaemic again, but the underlying disorder in glucose metabolism apparently makes 
them prone to type 2 diabetes development. This prompted us to study these individuals as a model for 
type 2 diabetes predisposition and analyse the N-glycosylation of their plasma proteins as a potential 
biological marker which can expose this latent disorder in glycaemic control. 
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Glycosylation is the most frequent co- and post-translational modification of proteins, which in 
many cases modulates their function (4). Contrary to glycation (which is a non-enzymatic chemical 
reaction), this highly complex enzymatic process is strictly regulated by the network of many enzymes, 
transcriptional factors, sugar nucleotides and other molecules (5). The great amount of energy that 
organism invests in glycosylation indicates its importance, which has been proven in almost all 
physiological processes as well as in the aetiology of many diseases (6). Although proteins possess well 
defined glycosylation sites, a great heterogeneity of their glycans exists. Human plasma N-glycome is quite 
stable within the individual (7), but is extremely sensitive to pathophysiological processes, reflecting  the 
cell state from the time of protein secretion (8). The main diagnostic deficit of glycans is in their low 
specificity, thus they are more frequently studied as prognostic and stratification markers. Their great 
variability within population, and the significant heritability rate, gives them a great potential in risk 
assessments. Changes in glycosylation of plasma proteins have been studied in many different diseases, 
including type 2 diabetes mellitus (9). These changes have been confirmed in both patients with diabetes 
and db/db mice (10; 11). Although many studies identified biantennary glycans with core fucose as 
structures of main interest, differences between cases and healthy population were never pronounced 
enough to have a diagnostic potential, probably as a result of relatively good glycaemic control in patients, 
administration of medicaments or existence of many different molecular mechanisms that lead to type 2 
diabetes development.  
Recent studies implicated glycosylation aberrations in the pathophysiology of diabetes. Ohtsubo 
K. et al showed  that elevated concentrations of free fatty acids, that comprise a pathogenic pathway to 
diabetes, cause nuclear exclusion and reduced expression of some transcription factors in beta cells, 
which results in a deficit of GnT-4a glycosyltransferase and hyperglycaemia, impaired glucose tolerance, 
hyperinsulinemia etc. (12). Enforced beta cell-specific GnT-4a protein glycosylation seems to prevent 
diabetes development through the maintenance of glucose transporter expression and the preservation 
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of glucose transport.  Recently, it was also shown that higher glucose levels lead to altered flux through 
the hexosamine pathway, which is considered to be an essential pathway in developing diabetes 
complications, as it produces UDP- GlcNAc, a substrate for N-linked glycosylation (13). 
The aim of this study was to determine whether plasma protein N-glycome is changed in individuals 
who are at greater risk of developing type 2 diabetes, using three different populations: 
1. Two populations including individuals with registered hyperglycaemia in critical illness (increased 
risk for development of type 2 diabetes) and individuals with normoglycaemia in critical illness -  
AcuteInflammation  and AcuteInflammation Replication populations; 
2. Individuals who developed type 2 diabetes during 10 years follow-up and those who remained 
normoglycaemic - FinRisk population.  
Also, to further confirm the connection of changes in N-glycome with glucose metabolism disruption, we 
used data from our previous plasma protein glycosylation analysis in two other cohorts (ORCADES and 
SABRE), where we separated age- and sex-matched individuals into two subgroups differing in HbA1c 
status (HbA1c<6.5 and HbA1c>6.5 %). 
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Study populations and methods 
Patients with/without hyperglycaemia during critical illness (AcuteInflammation and AcuteInflammation 
Replication populations) 
AcuteInflammation population - We included patients from a medical intensive care unit (ICU) at 
the University Hospital Centre Zagreb during a period of 6 months (February to July 2013). Adult (>18 
years old) patients with negative history of diabetes who were admitted to the ICU and discharged from 
the hospital alive were eligible for inclusion. Excluded were patients diagnosed with diabetes or 
prediabetes before or during hospitalization, patients with documented gestational diabetes, pregnant 
patients and patients taking glucocorticoids during or 3 months before the admission. Informed consent 
process was conducted by a member of the study team at the discharge from the ICU or the hospital. 
Consenting patients were asked to attend a follow-up appointment, 6-8 weeks after the hospital 
discharge. At this visit inclusion/exclusion criteria were confirmed. Complete blood count and CRP were 
determined to exclude persisting inflammatory process. Patients with elevated markers of inflammation 
were retested after 2 weeks. All patients underwent oral glucose tolerance test (OGTT) and measurement 
of HbA1c to identify pre-existing diabetes. ADA criteria for diagnosis of diabetes were employed and 
patients diagnosed with existing pre-diabetes or diabetes were excluded. Height, weight and BMI were 
recorded; family history of diabetes was documented. For all patients fasting blood samples for N-glycan 
profiling were collected in tubes with anticoagulants (both EDTA and citrate for each patient), plasma was 
separated immediately and stored at -20°C until the analysis. For each patient, samples were analysed in 
duplicates. In total, 108 patients were enrolled in the study. 
AcuteInflammation Replication population - All cardiac surgical patients operated at the University 
Hospital Centre Zagreb (cardiac surgical procedures employing cardiopulmonary bypass) from October 
2010 to February 2011 and discharged from the hospital alive were screened for the study. All participants 
provided written informed consent. Excluded were patients diagnosed with diabetes or prediabetes 
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before or during hospitalization. In total, 66 patients were enrolled in the study and from all of them blood 
was drawn on the day of the surgery, before the surgical procedure. The blood samples were collected in 
tubes containing EDTA, plasma was separated and stored at -20°C until analysis.  
Relevant demographic data for both populations are summarized in Table 1. 
 
Individuals who did/did not develop T2D within 10 years from sampling (FinRisk study) 
Plasma samples, stored at - 70°C, collected through the study designed to investigate risk factors 
in Finland population (14) were used. Population data were searched for patients with incident type 2 
diabetes after 10 years follow-up. Individuals who developed any autoimmune, malignant or other chronic 
disease were excluded. Thirty-seven individuals (aged 60 (34 - 72)), who developed type 2 diabetes and 
no other chronic disease, were identified and included in this study. Thirty-seven age and sex matching 
controls (age 61 (35 - 73)), who remained healthy during the follow-up period, were selected from the 
same population. 
 
Individuals with different HbA1c status (ORCADES and SABRE studies) 
Plasma samples from the  Orkney Complex Disease Study (ORCADES), collected in Scottish 
archipelago of Orkney, between 2005 and 2011 (15) as well as fromSABRE population were used (16). 
Data on age, sex and HbA1c levels were included in the study. Glycan data for aforementioned population 
had been obtained for another purpose, but was used in this study to compare N-glycomes of subjects 
with HbA1c<6.5% and HbA1c>6.5 %. From Orkney population glycan and HbA1c data for 752 participants 
aged 18 to 100 years from a subgroup of ten islands were used for this analysis. Consecutively, 658 
participants (aged 63 (18 - 97)) were identified as having HbA1c<6.5 % and 94 (aged 63 (19 - 88)) as having 
HbA1c>6.5 %. From SABRE population, data for 307 individuals (aged 70 (60 - 84)) with HbA1c<6.5 % and 
307 (aged 70 (60 -84)) with HbA1c>6.5 % were included. 
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All studies are supported by written informed consent from all participants and approvals from 
eligible local Ethics Committees.   
Glycan analysis 
Glycan release and labelling - Prior to analysis, all samples (cases and controls) have been 
randomized throughout the multi-well plates. For each plate 4 standards (pool of plasma samples) have 
been added to minimize the experimental error.  Each plasma sample (10 μL) was denatured with the 
addition of 20 μL of 2 % SDS (w/v) (Invitrogen, Carlsbad, CA, USA) and by incubation at 65 °C for 10 min. 
Subsequently, 10 μL of 4 % Igepal-CA630 (Sigma-Aldrich, St. Louis, MO, USA) and 1.25 mU PNGase F 
(ProZyme, Hayward, CA, USA) in 10 μL 5× PBS were added. The samples were incubated overnight at 37 
°C for N-glycan release. The released N-glycans were labelled with 2-aminobenzamide (2-AB). The labelling 
mixture was freshly prepared by dissolving 2-AB (19.2 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) and 2-
picoline borane (44.8 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) in DMSO (Sigma-Aldrich, St. Louis, MO, 
USA) and glacial acetic acid (Merck, Darmstadt, Germany) mixture (70:30, v/v). Labelling mixture (25 μL) 
was added to each N-glycan sample in the 96-well plate, which was then sealed using adhesive seal. Mixing 
was achieved by shaking for 10 min, followed by two-hour incubation at 65 °C. Samples (in a volume of 
75 μL) were brought to 80% ACN (v/v) by adding 300 μL of ACN (J.T. Baker, Phillipsburg, NJ, USA). Free 
label and reducing agent were removed from the samples using HILIC-SPE. To each well of a 0.45 μm GHP 
filter plate (Pall Corporation, Ann Arbor, MI, USA) 200 μL of 0.1 g/mL suspension of microcrystalline 
cellulose (Merck, Darmstadt, Germany) in water was added. Solvent was removed by application of 
vacuum using a vacuum manifold (Millipore Corporation, Billerica, MA, USA). All wells were prewashed 
using 5× 200 μL of water, followed by equilibration using 3× 200 μL of acetonitrile/water (80:20, v/v). The 
samples were loaded to the wells, which were subsequently washed 7× using 200 μL of acetonitrile/water 
(80:20, v/v). Glycans were eluted 2× with 100 μL of water and combined eluates were stored at −20 °C 
until usage. 
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Hydrophilic Interaction Chromatography (HILIC)-UPLC - Fluorescently labelled N-glycans were 
separated by hydrophilic interaction chromatography on Waters Acquity ultra-performance liquid 
chromatography (UPLC) instrument (Milford, MA, USA) consisting of a quaternary solvent manager, 
sample manager and a FLR fluorescence detector set with excitation and emission wavelengths of 250 
and 428 nm, respectively. The instrument was under the control of Empower 2 software, build 2145 
(Waters, Milford, MA, USA). Labelled N-glycans were separated on a Waters bridged ethylene hybrid (BEH) 
Glycan chromatography column, 150 × 2.1 mm, 1.7 μm BEH particles, with 100 mM ammonium formate, 
pH 4.4, as solvent A and acetonitrile as solvent B. The separation method used a linear gradient of 70–
53% acetonitrile (v/v) at flow rate of 0.561 ml/min in a 25 min analytical run. Samples were maintained at 
5 °C before injection, and the separation temperature was 25 °C. The system was calibrated using an 
external standard of hydrolysed and 2-AB labelled glucose oligomers from which the retention times for 
the individual glycans were converted to glucose units. Data processing was performed using an automatic 
processing method with a traditional integration algorithm after which each chromatogram was manually 
corrected to maintain the same intervals of integration for all the samples. The chromatograms were all 
separated in the same manner into 46 peaks (GP1-GP46) and the amount of glycans in each peak was 
expressed as % of total integrated area (Fig 1). 
 
Statistical analysis 
In order to remove experimental variation from measurements, normalization and batch 
correction were performed on UPLC glycan data. Also, normalization by total area was performed in which 
the peak area of each glycan peak was divided by the total area of the corresponding chromatogram. Prior 
to batch correction, normalized glycan measurements were log-transformed due to right skewness of 
their distributions and the multiplicative nature of batch effects. Batch correction was performed on log-
11 
 
transformed measurements using the ComBat method, in which the technical source of variation (which 
sample was analysed on which plate) was modelled as a batch covariate. To get measurements corrected 
for experimental noise, estimated batch effects were subtracted from log-transformed measurements. 
From the 46 directly measured glycan traits, 12 derived traits were calculated. These include: 
Structural feature Formula 
low branching LB = GP1+GP2+GP3+GP4+GP5+GP6+GP7+GP8+GP9+GP10+GP11+GP12+GP13+GP14+GP15+GP16+GP17+ 
GP18+GP19+GP20+GP21+GP22+GP23+GP24+GP25+GP26+GP27+GP28 
high branching HB = 
GP29+GP30+GP31+GP32+GP33+GP34+GP35+GP36+GP37+GP38+GP39+GP40+GP41+GP42+GP43+GP44+GP45+GP46 
agalactosylated G0 = GP1+GP2+GP4+GP5+GP6 
monogalactosylate
d 
G1 = GP3+GP7+GP8+GP9+GP10+GP16+GP17+GP18 
digalactosylated G2 = GP12+GP13+GP14+GP15+GP19+GP20+GP21+GP22+GP23+GP25+GP26+GP27+GP28 
trigalactosylated G3 = GP29+GP31+GP32+GP33+GP34+GP35+GP36+GP37+GP40 
tetragalactosylated G4 = GP30+GP38+GP39+GP41+GP42+GP43+GP44+GP45+GP46 
neutral S0 = GP1+GP2+GP3+GP4+GP5+GP6+GP7+GP8+GP9+GP10+GP11+GP12+GP13+GP14+GP15 
monosialylated S1 = GP16+GP17+GP18+GP19+GP20+GP21+GP22+GP30 
disialylated S2 = GP23+GP25+GP26+GP27+GP28+GP29+GP31 
trisialylated S3 = GP32+GP33+GP34+GP35+GP36+GP37+GP38+GP39+GP40 
tetrasialylated S4 = GP41+GP42+GP43+GP44+GP45+GP46 
 
These derived traits average particular glycosylation features (branching, galactosylation, sialylation) 
across different individual glycan structures, and consequently they are more closely related to individual 
enzymatic activities and underlying genetic polymorphisms. As derived traits represent sums of directly 
measured glycans, they were calculated using normalized and batch-corrected glycan measurements after 
transformation to the proportions (exponential transformation of batch-corrected measurements). 
Analyses of associations between clinical trait of interest (AcuteInflammation and 
AcuteInflammation Replication  - hyperglycaemia ;  FinRisk Cohort - future onset of diabetes; ORCADES & 
SABRE Cohorts - HbA1C > 6.5 %) and glycan measurements were performed using a regression model with 
age and sex included as additional covariates. Prior to analyses, for each cohort separately, glycan 
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variables were transformed to a standard normal distribution by inverse transformation of ranks to 
normality. Using rank-transformed variables makes estimated effects of different glycans in different 
cohorts comparable, as transformed glycan variables have the same standardized variance. The false 
discovery rate (FDR) was controlled using the Benjamini-Hochberg procedure.  
Data were analysed and visualized using R programming language (version 3.0.1).  
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Results 
Analysis of plasma N-glycome composition in AcuteInflammation and AcuteInflammation Replication 
populations 
For each patient, N-glycans were released from plasma proteins, fluorescently labelled and 
analysed by HILIC-UPLC, a method that was demonstrated to be the best approach for reliable and 
reproducible quantitative glycan analysis (17). This method separates plasma glycome into 46 
chromatographic peaks, each containing a group of similar glycan structures. Individual glycan structures 
contained in each peak were characterized previously (18) and representative chromatogram with main 
structure present in each peak is shown in Fig 1.  
Next, we quantified each chromatographic peak (as % of the total N-glycome) and calculated derived 
traits (for more details see Methods section). These derived traits represent common biologically 
meaningful features (glycan branching, galactosylation and sialylation) shared among several measured 
glycans. Then we compared these traits between two groups of patients in two populations:  
1. Those who developed hyperglycaemia during ICU hospitalization due to acute condition and those 
who remained normoglycaemic during the same circumstances (AcuteInflammation population, 
Table 1) – for the analysis, plasma samples taken 6-8 weeks after the hospital discharge were 
used, and meanwhile the absence of inflammatory process was also confirmed (acquired profiles 
thus represented basal N-glycomes for each person); 
2. Those who developed hyperglycaemia after cardiac surgery due to acute inflammation and those 
who remained normoglycaemic after the surgery (AcuteInflammation Replication population, 
Table 1) – for the analysis, plasma samples taken on the day of the surgery, before the surgical 
procedure were used. 
The development of hyperglycaemia during acute inflammation represents significantly higher risk for 
type 2 diabetes development (2; 3).  
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Figure 2 and Table 2 show differences in abundance of derived structural features of plasma protein 
N-glycans in individuals who developed hyperglycaemia during acute condition and controls. Differences 
are shown as the effect sizes estimated based on logistic regression (logarithm of odds ratio). In 
AcuteInflammation population, six derived traits were significantly different between the two groups – 
patients who developed hyperglycaemia had decreased low branching (LB) and increased high branching 
(HB), increased tri- and tetragalactosylation (G3 and G4), decreased neutral glycans (S0) and increased 
trisialylation (S3).  
The differences found in AcuteInflammation Replication population showed the same trend and 
similar magnitude of changes, as found in the AcuteInflammation population for almost all derived traits, 
except for digalactosylation (G2). However, none of them reached statistical significance. 
 
Analysis of plasma N-glycome composition in FinRisk populations 
Differences in plasma protein N-glycome between individuals who will or will not develop type 2 
diabetes was further valuated in the FinRisk study cohort, in which plasma samples were collected more 
than 10 years ago and biobanked. The 10-year follow-up has been performed to note the incidence of 
type 2 diabetes. Thirty-seven individuals who developed type 2 diabetes and no other chronic disease and 
37 age and sex matching controls, who remained healthy during follow-up period, were identified and 
included in the study. Plasma N-glycome was analysed in the same way as for the previous two 
populations.  
Individuals who developed type 2 diabetes had significantly decreased LB and increased HB, 
decreased agalactosylation and monogalactosylation (G0 and G1), decreased neutral glycans (S0) and 
increased di- and tri-sialylation (S2 and S3), compared to individuals who remained normoglycaemic (Fig 
2 and Table 2). For all derived glycan traits, differences found in FinRisk were in the same direction and of 
similar magnitude, as found in AcuteInflammation population. 
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Analysis of plasma N-glycome composition in ORCADES and SABRE populations 
To further prove the connection of N-glycome with glucose metabolism disruption, we used data 
from our previous analysis of plasma protein glycosylation in two other cohorts (ORCADES and SABRE), 
where we separated age- and sex-matched individuals into two subgroups differing in HbA1c status 
(HbA1c<6.5 % and HbA1c>6.5 %). 
We compared the differences between the two subgroups in the same way as in the previous 
populations.  Levels of the majority of glycan features were significantly different between the studied 
subgroups (10 for ORCADES and 7 for SABRE) (Fig 2 and Table 2). Main differences were the same as in 
the previous populations - higher levels of branching, galactosylation and sialylation in their plasma 
protein N-glycomes. 
 
Conclusions 
Our results indicate that plasma protein N-glycome is changed in individuals with increased risk 
for type 2 diabetes development (AcuteInflammation and AcuteInflammation Replication populations), 
incident cases of type 2 diabetes collected at baseline (FinRisk population) and people with increased 
HbA1c (ORCADES and SABRE populations). Differences in plasma N-glycomes were the same in all three 
populations and included higher levels of branching, galactosylation and sialylation. This suggests that the 
increased complexity of glycan structures represents the greater chance for diabetes type 2 development 
and is also associated with poorer regulation of blood glucose levels.   
One can only speculate whether these differences in plasma glycome are inborn and genetically 
conditioned, or glycosylation is affected by the pathophysiological mechanisms that occur very early at 
diabetes onset and manifest themselves in the changes of the plasma glycome composition due to high 
susceptibility of glycans to changes in the cell metabolism. A possible explanation for this higher branching 
could be that higher glycaemia leads to altered flux through the hexosamine pathway, which produces 
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UDP-GlcNAc, the substrate for N-linked glycosylation (12). Recently, it has also been shown that the 
hexosamine biosynthesis and GlcNAc salvage pathways contribute to glucose homeostasis through N-
glycan branching on glucagon receptor (13). 
Previous studies showed that multi-branched and highly sialylated N-glycans were also elevated 
in response to inflammatory diseases, such as ulcerative colitis (19), chronic pancreatitis (20) and 
rheumatoid arthritis (21). It is also well known that subjects with metabolic syndrome and type 2 diabetes 
suffer from chronic low-grade inflammation (22). Therefore, the N-glycan changes that were observed in 
this study may also reflect the chronic inflammatory processes. Additional support for this hypothesis 
comes from our recent study of a NMR biomarker GlycA and total plasma protein N-glycome. GlycA is a 
signal that measures N-acetylglucosamines attached to the plasma proteins and it has been shown to 
correlate with wide spectra of inflammatory diseases, including incident type 2 diabetes mellitus (23; 24). 
In that study we found that GlycA signal was positively related to highly branched structures, as well as 
tri- and tetragalactosylated and tri- and tetrasialylated structures, while low branched glycans, 
agalactosylated, monogalactosylated, asialylated and monosialylated structures were negatively 
associated with GlycA signal (25). These changes are practically the same as found herein, which suggests 
that the changes in plasma protein N-glycome could indicate the start of chronic inflammation and the 
susceptibility for developing metabolic syndrome. This could also explain why the differences in derived 
glycan traits between the cases and controls in AcuteInflammation Replication population did not reach 
the threshold of significance – all individuals from this population had cardiovascular diseases and 
underwent cardiac surgery. Therefore, it is possible that most of them (both cases and controls) already 
had some kind of chronic inflammation. The other possible reason for this could be that the control group 
was too small (14 individuals). 
Despite the fact that we measured the whole plasma protein N-glycome, which is comprised of 
different glycans originating from many different glycoproteins, we managed to find differences in glycan 
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traits between the controls and seemingly healthy individuals, who have a higher chance or will develop 
type 2 diabetes mellitus.  The same changes were also associated with poorer regulation of blood glucose. 
Identifying the exact glycoproteins which contribute to these differences would probably help to develop 
stratification methods that could reliably distinguish individuals who are at risk of type 2 diabetes 
development and improve the prevention of this widespread disease and its complications.  
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Figure legends 
 
Figure 1. HILIC-UPLC profile of N-linked glycans released from plasma proteins and fluorescently labelled 
with 2-aminobezamide. Glycans presented are the most abundant structures in each peak. 
 
Figure 2. Differences in abundance of structural features of plasma protein N-glycans in individuals who 
developed hyperglycaemia during acute condition (AcuteInflammation and AcuteInflammation 
Replication populations - darkest grey and dark grey); in individuals from FinRisk population who 
developed type 2 diabetes during 10-year follow-up (grey); in individuals from ORKNEY population (light 
grey) and SABRE population (white) divided according to HbA1c level (< or > 6.5 %). Pronounced 
differences were observed between cases and controls in all cohorts for several derived glycan structural 
features. Differences in derived glycan traits are shown as bar plots where height of bars represents the 
size of effects estimated based on logistic regression (logarithm of odds ratio) and error bars represent 95 
% confidence intervals of estimated effects. (LB - low branching, sum of monoantennary and biantennary 
glycans, see Methods section; HB - high branching, sum of triantennary and tetraantennary glycans; G0 - 
sum of glycans with no galactose; G1 - sum of glycans with one galactose; G2 - sum of glycans with two 
galactoses; G3 - sum of glycans with three galactoses; G4 - sum of glycans with four galactoses; S0 - sum 
of glycans with no sialic acid; S1 - sum of glycans with one sialic acid; S2 - sum of glycans with two sialic 
acids; S3 - sum of glycans with three sialic acids, S4 - sum of glycans with four sialic acids).  
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Tables 
Table 1. The demographic characteristics of AcuteInflammation and AcuteInflammation Replication 
populations  
  All patients HG during acute illness No HG during acute illness  P value (HG vs. no HG)* 
Population AI AI_R  AI AI_R  AI AI_R  AI AI_R 
Number of patients (N) 108 66 59 52 49 14     
Age (y) 55 (18 - 79) 67 (21 - 81) 58 (25 - 79) 68 (41 - 81) 54 (18 - 75) 62 (21 - 78) 0.388 0.121 
Female sex (N,%) 32 (29.6%) 19 (28.8%) 18 (30.5%)  15 (28.8%) 14 (28.6%) 4 (28.6%) 0.826 0.984 
BMI (kg/m2) 23.7±4.0 28.2±3.5 24.2±4.1 28.5±3.4 23.1±3.9 27.2±3.8 0.734 0.342 
Family history of diabetes (N,%) 27 (25.0%) NA 19 (32.2%) NA 8 (16.3%) NA 0.039 NA 
 
(AI - AcuteInflammation; AI_R - AcuteInflammation Replication; HG - hyperglycaemia; BMI - body mass index) 
* p-values were calculated using Mann-Whitney U test (significance level α=0.05); for categorical variables Chi-square test was 
used
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Table 2. Differences in derived structural features of plasma protein N-glycans between the cases and the controls in all five populations. Differences are shown as effects estimated based on logistic 
regression (logarithm of odds ratio).  
 
  AcuteInflammation AcuteInflammation_R FinRisk ORCADES SABRE 
derived 
 glycan trait 
effect SE P value adj. P value effect SE P value adj. P value effect SE P value adj. P value effect SE P value adj. P value effect SE P value adj. P value 
LB -0.480 0.179 0.006 0.016 -0.344 0.342 0.281 0.393 -0.517 0.230 0.022 0.040 -0.384 0.119 0.001 0.002 -0.284 0.077 0.000 0.001 
HB 0.448 0.180 0.010 0.024 0.344 0.342 0.281 0.393 0.517 0.230 0.022 0.040 0.388 0.119 0.001 0.002 0.339 0.077 0.000 0.000 
G0 -0.186 0.154 0.209 0.276 -0.023 0.327 0.940 0.956 -0.447 0.206 0.027 0.045 -0.276 0.113 0.014 0.019 -0.052 0.080 0.511 0.558 
G1 -0.359 0.184 0.044 0.068 -0.257 0.326 0.399 0.498 -0.603 0.225 0.007 0.017 -0.611 0.119 0.000 0.000 -0.440 0.074 0.000 0.000 
G2 0.027 0.182 0.878 0.878 -0.312 0.332 0.314 0.428 0.250 0.217 0.236 0.290 0.036 0.118 0.759 0.759 0.097 0.079 0.213 0.276 
G3 0.399 0.163 0.011 0.024 0.458 0.343 0.153 0.236 0.459 0.230 0.041 0.066 0.403 0.118 0.001 0.002 0.403 0.076 0.000 0.000 
G4 0.406 0.190 0.027 0.045 0.099 0.335 0.750 0.818 0.198 0.234 0.381 0.446 0.276 0.120 0.021 0.025 0.024 0.079 0.756 0.789 
S0 -0.413 0.167 0.011 0.024 -0.271 0.332 0.380 0.487 -0.630 0.221 0.004 0.012 -0.455 0.119 0.000 0.001 -0.297 0.077 0.000 0.001 
S1 -0.091 0.196 0.627 0.669 -0.581 0.310 0.047 0.083 -0.171 0.224 0.429 0.478 -0.354 0.120 0.003 0.005 -0.096 0.080 0.230 0.290 
S2 0.298 0.174 0.077 0.111 0.468 0.329 0.129 0.204 0.565 0.226 0.011 0.024 0.547 0.120 0.000 0.000 0.327 0.077 0.000 0.000 
S3 0.517 0.181 0.003 0.010 0.252 0.341 0.428 0.514 0.525 0.230 0.020 0.039 0.358 0.121 0.003 0.005 0.319 0.077 0.000 0.000 
S4 0.331 0.204 0.093 0.128 0.038 0.333 0.902 0.933 0.209 0.229 0.347 0.416 0.195 0.122 0.106 0.115 0.063 0.079 0.424 0.478 
 
(LB - low branching, sum of monoantennary and biantennary glycans, see Methods section; HB - high branching, sum of triantennary and tetraantennary glycans; G0 - sum of glycans with no galactose; G1 - sum of glycans with one galactose; G2 - sum 
of glycans with two galactoses; G3 - sum of glycans with three galactoses; G4 - sum of glycans with four galactoses; S0 - sum of glycans with no sialic acid; S1 - sum of glycans with one sialic acid; S2 - sum of glycans with two sialic acids; S3 - sum of 
glycans with three sialic acids, S4 - sum of glycans with four sialic acids; SE - standard error; adj. P value – P value corrected for multiple measures using Benjamini-Hochberg procedure) 
